Global - English
Brazil - Portuguese
Thailand - Thai
Middle East - Arabic
Vietnam - Vietnamese
Spain - Spanish
Colombia - Spanish
Argentina - Spanish
At a Glance
The pharmaceutical drug development process is a structured, evidence-driven pathway used to determine whether a promising candidate can be developed into a medicine with an appropriate quality, safety and efficacy profile. It encompasses discovery and nonclinical research, clinical development, regulatory assessment and post-market monitoring, while formulation, analytical, stability and regulatory activities evolve in parallel to support development decisions.
Key points for development teams
- The five broad stages of drug development should not be confused with the Phase I–IV clinical trial framework.
- Formulation, analytical and stability activities can influence downstream development decisions.
- Each stage should generate evidence that enables a clear, risk-informed decision on the next step.
- For programmes intended for India, regulatory strategy should be considered early and aligned with applicable CDSCO requirements.
What Is the Pharmaceutical Drug Development Process?
The pharmaceutical drug development process transforms a promising candidate into a medicine supported by robust scientific, quality, safety, and efficacy evidence at every stage of development. It assesses whether the product can be developed and manufactured consistently, administered at an appropriate dose and supported by the evidence required for its intended regulatory pathway.
Although drug development is often presented as a sequence of discrete stages, in practice it is an integrated programme of interdependent decisions. Clinical strategies are informed by preceding nonclinical findings; regulatory submissions rely on complete, consistent and traceable data; and product quality is shaped by formulation, analytical methods, stability evidence and control strategies that mature throughout development.
In this context, medication development refers to the evidence-generation activities that follow the identification of a promising candidate. The scope extends well beyond clinical trials, encompassing the progressive development of the medicine’s dosage form, quality attributes, analytical controls and overall control strategy alongside the clinical programme.
The United States Food and Drug Administration presents the broad lifecycle as discovery and development, preclinical research, clinical research, regulatory review and post-market safety monitoring. See the FDA lifecycle overview ↗
What Are the Five Stages of Drug Development?
The pharmaceutical drug development lifecycle is commonly described through five broad stages: discovery and development, preclinical research, clinical research, regulatory review and post-market safety monitoring. While each stage addresses distinct scientific and regulatory questions, product quality, analytical, regulatory and development activities continue to evolve throughout the programme.
Discovery and candidate selection
Researchers identify therapeutic opportunities and evaluate potential candidates. The objective is to select a candidate with sufficient rationale and supporting evidence to justify progression into focused development.
Preclinical development
Nonclinical studies evaluate pharmacology, safety and the candidate’s behaviour before exposure in humans. In parallel, product and analytical development generates the information required to characterise the candidate, assess development risks and support the transition to subsequent stages.
Clinical development
Clinical development evaluates the medicine in human subjects through appropriately designed protocols addressing defined questions of safety, dose, tolerability and efficacy.
Regulatory review
During regulatory review, the sponsor submits a dossier integrating the relevant quality, nonclinical and clinical evidence for assessment by the applicable regulatory authority.
Post-market monitoring
Following approval, ongoing oversight remains essential. Safety information, product quality, and lifecycle changes may require continued monitoring, assessment and evidence management throughout the product’s commercial life.
Where Does Drug Discovery End and Development Begin?
Drug discovery focuses on identifying and optimising promising candidates, whereas drug development begins when a selected candidate is advanced into a structured programme of product, nonclinical, clinical and regulatory development. The objective is to generate the evidence required to determine whether the candidate can ultimately become a viable medicine.
Drug discovery
Drug discovery may encompass target identification and validation, hit identification, hit-to-lead activities and lead optimisation. Collectively, these activities seek to identify and refine a candidate with sufficient scientific rationale and potential to warrant further development.
Drug development
Once a candidate is selected, drug development focuses on establishing an appropriate dosage form and dose, generating safety and clinical evidence, defining manufacturing and quality controls, and building regulatory readiness. The transition from discovery to development is not necessarily marked by a single point in time; rather, the purpose and maturity of the evidence evolve.
Important scope note: The process of drug discovery and development spans distinct but connected disciplines. Drug discovery establishes candidate rationale; development builds the product, nonclinical, clinical and regulatory evidence required to progress the selected candidate.
When people refer to the stages of drug discovery and development, the stages of drug discovery may also be described as drug discovery phases. Together with subsequent development, they form the broader drug discovery and development process and clarify how candidate rationale is carried into evidence generation.
What Happens Before Clinical Trials Begin?
Before a candidate can progress into clinical development, the sponsor needs a body of evidence sufficient to support the transition from laboratory and nonclinical research to studies in humans. In parallel, the product must be supported by an appropriate quality and development package aligned with the proposed stage, dosage form and route of administration.
Nonclinical development may encompass pharmacology, toxicology and exposure-related studies. In parallel, product development must address the intended dosage form, manufacturing approach, analytical methodology, specifications and stability profile. The International Council for Harmonisation (ICH) sets internationally harmonised principles for the timing of nonclinical safety studies in relation to clinical trials. Read ICH M3(R2) ↗
| Workstream | What it needs to answer | Typical output |
|---|---|---|
| Nonclinical evidence | What is known about pharmacology, safety and exposure before human studies? | A package that supports the proposed clinical entry and risk assessment. |
| Formulation development | Which dosage form and formulation composition can consistently achieve the intended product performance and quality attributes? | A stage-appropriate formulation strategy and development record. |
| Analytical development | How will identity, strength, purity and other critical quality attributes be reliably characterised and quantified? | Methods and controls that are suitable for the development stage. |
| Stability programme | How does the product’s quality profile change over time under defined storage conditions, and what do the resulting data indicate for storage, retest or shelf-life considerations? | Data that informs storage, retest or shelf-life decisions as applicable. |
These activities are commonly brought together under Chemistry, Manufacturing and Controls (CMC). CMC should not be viewed as documentation added at the end of development; it is the integrated body of product and process knowledge that enables a medicine to be manufactured, tested and controlled consistently as the programme advances.
What Are Phase I, II, III and IV Clinical Trials?
Clinical phases represent the human-study component of the broader drug development lifecycle. Phase I generally focuses on initial safety, tolerability and dose-related questions; Phase II generates preliminary evidence of activity while further characterising dose and safety; Phase III provides confirmatory evidence of benefit and risk; and Phase IV encompasses post-marketing studies and ongoing evidence generation.
| Clinical phase | Primary development question | How it informs the next decision |
|---|---|---|
| Phase I | How is the product tolerated in humans, and what does early clinical exposure reveal about safety, pharmacokinetics and dose? | Supports dose selection and the design of subsequent studies. |
| Phase II | What preliminary evidence is available regarding clinical activity, dose selection and safety in the target patient population? | Refines the development hypothesis and later study design. |
| Phase III | Does the programme generate sufficiently robust confirmatory evidence to characterise the benefit–risk profile for the proposed indication? | Forms a central part of the evidence considered for marketing authorisation. |
| Phase IV | What additional evidence on safety, effectiveness or real-world use is required following approval? | Supports ongoing pharmacovigilance and lifecycle management. |
The exact design for the clinical development of drug candidates depends on the product, indication, patient population and authority expectations. The FDA describes clinical research as studies in people conducted through a protocol, with early small-scale studies progressing to larger Phase III studies. Read the FDA clinical research overview ↗
How Do Development Workstreams Run in Parallel?
Pharmaceutical drug development is not a linear relay in which one function simply hands work to the next. Formulation, analytical, stability, regulatory, clinical and manufacturing activities frequently progress in parallel because a change in one workstream can influence product quality, specifications, supply, the regulatory dossier and the feasibility of subsequent development milestones.
Product and formulation
Translates the target product profile into an appropriate dosage form, formulation composition and manufacturing strategy capable of progressing through the relevant stages of development.
Analytical and stability
Develops the analytical methods and stability evidence required to characterise product quality, monitor changes over time and establish scientifically justified specifications and storage considerations.
Clinical and regulatory
Maintains alignment between clinical protocols, emerging safety information, development evidence and evolving regulatory submission requirements.
Quality and supply readiness
Integrates quality controls, documentation and manufacturing readiness to ensure that clinical supplies and later-stage product requirements remain appropriately supported as development progresses.
For development teams, the critical question is not simply, “What stage are we in?” but also, “What evidence, technical gap or product decision could prevent the next milestone from being achieved as planned?” A decision-led approach helps identify uncertainties early, when they can be evaluated and addressed before they become more significant development constraints.
How Is New Drug Development Regulated in India?
For programmes intended for the Indian market, new drug development and clinical-trial planning should be aligned with the applicable Central Drugs Standard Control Organisation (CDSCO) framework and the New Drugs and Clinical Trials Rules, 2019. Specific requirements vary according to the product, development pathway and proposed regulatory activity.
For programmes targeting India, regulatory strategy should be integrated into development planning from an early stage, ensuring that the scientific programme, CMC information and proposed clinical activities remain aligned with the applicable regulatory pathway rather than being addressed only when the dossier is assembled. This early alignment is therefore a core consideration in the process of new drug development for the Indian market.
- 1Plan the regulatory route early. Regulatory strategy should not be treated as a downstream documentation exercise. The evidence-generation plan, CMC package and proposed clinical activities should remain coherent and mutually aligned throughout development.
- 2Use current authority materials. Regulatory requirements and processes may evolve. Development teams should therefore consult current guidance, regulatory resources and authority communications applicable to the specific product and pathway rather than relying solely on historical requirements.
- 3Separate universal science from local procedure. While the underlying scientific and evidence-generation principles are broadly international, submission requirements, authority interactions and legal or procedural expectations remain jurisdiction-specific.
The CDSCO new-drugs area includes material on clinical-trial and new-drug review activities, including CMC and study-related information. View CDSCO new-drug resources ↗ Read the Rules ↗
What Happens After Regulatory Approval?
Regulatory approval represents a major milestone, but it is not the end of product stewardship. Post-market activities may include ongoing safety monitoring, adverse-event reporting, product-quality oversight, lifecycle management and, where appropriate, additional studies that expand the evidence base in real-world use.
The post-approval phase closes the loop between development evidence and ongoing product stewardship. It also underscores the importance of maintaining clear documentation, robust quality systems and traceable development rationale throughout the product lifecycle. Post-market monitoring should therefore be viewed not as an isolated obligation, but as a continuation of evidence-based product management. FDA’s lifecycle model identifies post-market safety monitoring as a distinct stage after review. Read the FDA post-market overview ↗
Pharmaceutical Drug Development Process FAQs
What are the five main steps of developing a drug?
The five broad stages are discovery and development, preclinical research, clinical research, regulatory review and post-market safety monitoring. Terminology may vary across regulatory frameworks, but the underlying progression of evidence and development decisions is broadly consistent.
What is the difference between drug discovery and drug development?
Drug discovery focuses on identifying and optimising promising candidates, while drug development generates the product, nonclinical, clinical and regulatory evidence required to determine whether a selected candidate can progress into a viable medicine. The two disciplines are closely connected, but their scientific objectives and development decisions are distinct.
What are the phases of pharmaceutical development?
The term “phases of pharmaceutical development” may refer either to the broader stages of the product lifecycle or specifically to clinical trial phases. For clarity, the two should be distinguished: the broader lifecycle encompasses discovery, preclinical development, clinical research, regulatory review and post-market monitoring, while clinical trials are commonly described as Phases I–IV.
What does “phase drug development” mean?
The phrase phase drug development, like searches for phases in pharmaceutical development, is usually used to ask about stages in the lifecycle or about clinical trial phases. The phases of drug development are clearer when separated into five broad lifecycle stages and the four clinical phases that sit within the clinical-research part of the programme.
What is the role of CMC in a new drug development process?
Chemistry, Manufacturing and Controls (CMC) brings together the information required to understand how the drug substance and drug product are manufactured, tested and controlled. Within drug development, CMC connects formulation, analytical methods, specifications, stability and manufacturing readiness with the evidence required to support progression through each stage.
How does the drug development process in clinical research differ from the full lifecycle?
Drug development within clinical research focuses specifically on the planning, conduct and interpretation of human studies. The full pharmaceutical development lifecycle is broader, encompassing discovery context, nonclinical research, CMC development, regulatory review and post-market monitoring.
Coordinating the Pharmaceutical Development Programme
Planning a pharmaceutical development programme requires more than progressing from one stage to the next—it requires coordination across formulation, analytical, stability, regulatory and quality workstreams. An integrated development approach can help identify critical requirements, manage evidence and support informed decisions at each milestone.
About Molkem Labs
Molkem Labs supports pharmaceutical development through formulation development, analytical and microbiological services, stability studies, regulatory support, technology transfer and coordination with Contract Manufacturing Organisations (CMOs). Development scope is defined according to the product and target market.
